State Street
EGRX

State Street’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

State Street’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,820
Closed -$134K – 4370
2024
Q3 		$134K Hold
35,820
– – ﹤0.01% 3920
2024
Q2 		$201K Sell
35,820
-177,847
-83% -$775K ﹤0.01% 3829
2024
Q1 		$1.12M Sell
213,667
-8,927
-4% -$49K ﹤0.01% 3441
2023
Q4 		$1.16M Buy
222,594
+14,823
+7% +$146K ﹤0.01% 3453
2023
Q3 		$3.28M Sell
207,771
-29,941
-13% -$538K ﹤0.01% 3119
2023
Q2 		$4.62M Sell
237,712
-165,206
-41% -$3.92M ﹤0.01% 3032
2023
Q1 		$11.4M Sell
402,918
-549,108
-58% -$16.3M ﹤0.01% 2583
2022
Q4 		$27.8M Sell
952,026
-59,721
-6% -$1.9M ﹤0.01% 2008
2022
Q3 		$26.7M Buy
1,011,747
+235,887
+30% +$8.66M ﹤0.01% 2018
2022
Q2 		$34.5M Buy
775,860
+59,976
+8% +$2.75M ﹤0.01% 1878
2022
Q1 		$35.4M Buy
715,884
+7,660
+1% +$368K ﹤0.01% 1977
2021
Q4 		$36.1M Sell
708,224
-721
-0.1% -$37.4K ﹤0.01% 2046
2021
Q3 		$39.5M Sell
708,945
-28,841
-4% -$1.42M ﹤0.01% 1985
2021
Q2 		$31.6M Sell
737,786
-64,798
-8% -$2.67M ﹤0.01% 2190
2021
Q1 		$33.5M Sell
802,584
-11,517
-1% -$535K ﹤0.01% 2026
2020
Q4 		$37.9M Buy
814,101
+19,046
+2% +$891K ﹤0.01% 1818
2020
Q3 		$33.8M Buy
795,055
+15,258
+2% +$667K ﹤0.01% 1717
2020
Q2 		$37.4M Buy
779,797
+154,327
+25% +$7.7M ﹤0.01% 1625
2020
Q1 		$28.8M Buy
625,470
+14,879
+2% +$747K ﹤0.01% 1600
2019
Q4 		$36.7M Buy
610,591
+69,264
+13% +$4.13M ﹤0.01% 1730
2019
Q3 		$30.6M Sell
541,327
-114,809
-17% -$6.46M ﹤0.01% 1774
2019
Q2 		$36.5M Buy
656,136
+3,871
+0.6% +$202K ﹤0.01% 1693
2019
Q1 		$32.9M Sell
652,265
-174,470
-21% -$7.76M ﹤0.01% 1719
2018
Q4 		$33.3M Sell
826,735
-124,126
-13% -$6.4M ﹤0.01% 1619
2018
Q3 		$65.9M Buy
950,861
+283,619
+43% +$21.5M 0.01% 1348
2018
Q2 		$50.5M Sell
667,242
-152,673
-19% -$9.6M ﹤0.01% 1485
2018
Q1 		$43.2M Buy
819,915
+52,134
+7% +$3.03M ﹤0.01% 1513
2017
Q4 		$41M Sell
767,781
-207,234
-21% -$11.5M ﹤0.01% 1559
2017
Q3 		$58.2M Buy
975,015
+278,549
+40% +$16.9M 0.01% 1278
2017
Q2 		$54.9M Buy
696,466
+133,601
+24% +$10.9M ﹤0.01% 1306
2017
Q1 		$46.7M Sell
562,865
-90,656
-14% -$6.74M ﹤0.01% 1366
2016
Q4 		$51.9M Buy
653,521
+94,563
+17% +$6.87M ﹤0.01% 1250
2016
Q3 		$39.1M Buy
558,958
+103,020
+23% +$5.71M ﹤0.01% 1350
2016
Q2 		$17.7M Sell
455,938
-173,555
-28% -$7.23M ﹤0.01% 1840
2016
Q1 		$25.5M Buy
629,493
+246,262
+64% +$15.6M ﹤0.01% 1557
2015
Q4 		$34M Sell
383,231
-45,755
-11% -$3.61M ﹤0.01% 1377
2015
Q3 		$31.8M Sell
428,986
-8,644
-2% -$719K ﹤0.01% 1432
2015
Q2 		$35.4M Buy
437,630
+431,530
+7,074% +$28.1M ﹤0.01% 1470
2015
Q1 		$255K Buy
+6,100
New +$173K ﹤0.01% 3458
2014
Q2 		– Sell
-21,290
Closed -$271K – 3679
2014
Q1 		$271K Buy
+21,290
New +$289K ﹤0.01% 3424

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

State Street's EGRX Position: Q4 2024 in Review

State Street sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 35,820 shares — an estimated $134K sold.

State Street first reported a position in EGRX in Q1 2014 and held it in 40 quarters. The position peaked at $65.9M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • State Street reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • State Street sold 35,820 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $134K.
  • State Street first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 40 quarters.
  • State Street's Eagle Pharmaceuticals, Inc. position peaked at $65.9M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on State Street's 13F filing for Q4 2024, filed 14 Feb 2025.